@phdthesis{Brendtke2018,
  author    = {Brendtke, Rico},
  title     = {Entwicklungsaspekte eines Medizinproduktes zur Pr{\"a}vention und {\"U}berwachung von Hydrierungszust{\"a}nden},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-157181},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2018},
  abstract  = {Der demografische Wandel und das Populationswachstum stellen eine globale Herausforderung f{\"u}r die Gesundheitssysteme dar. Eine vielversprechende L{\"o}sungsstrategie liegt in der digitalen {\"U}berwachung, Pr{\"a}vention und Therapie akuter und chronischer Erkrankungen durch die Nutzung von innovativen Technologien aus dem Bereich der personalisierten Medizin. Die Digitalisierung in der {\"U}berwachung von Vitalparametern mittels Sensorik besitzt großes Potential f{\"u}r die l{\"a}ngere Gesunderhaltung der Patienten und somit die Entlastung der Gesundheitssyteme im Ganzen. Da Wassermangel f{\"u}r eine Vielfalt von Krankheiten einen Katalysator darstellt, ist die Hydratation ein wichtiger aber bislang nur invasiv zug{\"a}nglicher Vitalparameter. Zur Etablierung nicht invasiver Messungen des Wasserhaushaltes am Menschen wurde im Rahmen dieser Arbeit die Eignung der Mikrowellentechnologie untersucht. Dehydratation resultiert in der Ver{\"a}nderung des Osmolythaushaltes und beeinflusst biochemische Prozesse, was zur Entstehung von Morbidit{\"a}t f{\"u}hren kann. Im Rahmen der Arbeit werden Teilbereiche der Entwicklung eines Medizinproduktes abgebildet. Zu diesem Zweck wird die Machbarkeit der mikrowellenbasierten Analyse des Wasserhaushaltes in einer technischen Machbarkeitsstudie untersucht, um im zweiten Prozessschritt einen technischen Demonstrator in vitro und in vivo am Probanden erproben zu k{\"o}nnen. Hochfrequente elektromagnetische Wellen interagieren mit Molek{\"u}len, speziell Wasser. Enth{\"a}lt eine Probe freie Wassermolek{\"u}le, kann dies im reflektierten Signal detektiert werden. Zur {\"U}berpr{\"u}fung des Sensorsystems in vitro dienen humane 3D-Vollhautmodelle mit spezifischer Hydratation und Gewebedichte der Matrixkomponenten als standardisiertes Modell zur Untersuchung definierter Exsikkoseszenarien und des Einflusses verschiedener Modellkomplexit{\"a}ten. Die Eignungs{\"u}berpr{\"u}fung des Systems mit einem technischen Demonstrator des k{\"u}nftigen Medizinproduktes belegt die Anwendbarkeit des Messsystems zur Erfassung des relativen Wassergehaltes. Die Technologie zeichnet sich durch eine hohe Sensitivit{\"a}t bei der Destinktion von Proben mittels Frequenz- und Signalreflektionsdifferenzen aus. Neben den In-vitro-Testungen wird das entwickelte Sensorsystem aus regulatorischer Sicht zur klinischen Leistungs{\"u}berpr{\"u}fung vorbereitet und im Rahmen eines bewilligten Ethikvotums in vivo erprobt. Die Ergebnisse belegen die Machbarkeit der nichtinvasiven Erfassung des Wasserhaushaltes durch mikrowellenbasierte Messungen. Die Technologie birgt das Potential, in ein k{\"o}rpernahes Sensorsystem integriert zu werden, welches als Medizinprodukt zur pers{\"o}nlichen Gesundheits{\"u}berwachung zugelassen werden kann.},
  subject      = {Medizinprodukt},
  language  = {de}
}
@phdthesis{Ruecker2019,
  author    = {R{\"u}cker, Christoph},
  title     = {Development of a prevascularized bone implant},
  doi       = {10.25972/OPUS-17886},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-178869},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2019},
  abstract  = {The skeletal system forms the mechanical structure of the body and consists of bone, which is hard connective tissue. The tasks the skeleton and bones take over are of mechanical, metabolic and synthetic nature. Lastly, bones enable the production of blood cells by housing the bone marrow. Bone has a scarless self-healing capacity to a certain degree. Injuries exceeding this capacity caused by trauma, surgical removal of infected or tumoral bone or as a result from treatment-related osteonecrosis, will not heal. Critical size bone defects that will not heal by themselves are still object of comprehensive clinical investigation. The conventional treatments often result in therapies including burdening methods as for example the harvesting of autologous bone material. The aim of this thesis was the creation of a prevascularized bone implant employing minimally invasive methods in order to minimize inconvenience for patients and surgical site morbidity. The basis for the implant was a decellularized, naturally derived vascular scaffold (BioVaSc-TERM®) providing functional vessel structures after reseeding with autologous endothelial cells. The bone compartment was built by the combination of the aforementioned scaffold with synthetic β-tricalcium phosphate. In vitro culture for tissue maturation was performed using bioreactor technology before the testing of the regenerative potential of the implant in large animal experiments in sheep. A tibia defect was treated without the anastomosis of the implant's innate vasculature to the host's circulatory system and in a second study, with anastomosis of the vessel system in a mandibular defect. While the non-anastomosed implant revealed a mostly osteoconductive effect, the implants that were anastomosed achieved formation of bony islands evenly distributed over the defect. In order to prepare preconditions for a rapid approval of an implant making use of this vascularization strategy, the manufacturing of the BioVaSc-TERM® as vascularizing scaffold was adjusted to GMP requirements.},
  subject      = {Tissue Engineering},
  language  = {en}
}
@phdthesis{Baur2019,
  author    = {Baur, Florentin Philipp},
  title     = {Establishment of a 3D tumour model and targeted therapy of BRAF-mutant colorectal cancer},
  doi       = {10.25972/OPUS-17412},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-174129},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2019},
  abstract  = {Cancer remains after cardiovascular diseases the leading cause of death worldwide and an estimated 8.2 million people died of it in 2012. By 2030, 13 million cancer deaths are expected due to the growth and ageing of the population. Hereof, colorectal cancer (CRC) is the third most common cancer in men and the second in women with a wide geographical variation across the world. Usually, CRC begins as a non-cancerous growth leading to an adenomatous polyp, or adenoma, arising from glandular cells. Since research has brought about better understanding of the mechanisms of cancer development, novel treatments such as targeted therapy have emerged in the past decades. Despite that, up to 95\% of anticancer drugs tested in clinical phase I trials do not attain a market authorisation and hence these high attrition rates remain a key challenge for the pharmaceutical industry, making drug development processes enormously costly and inefficient. Therefore, new preclinical in vitro models which can predict drug responses in vivo more precisely are urgently needed. Tissue engineering not only provides the possibility of creating artificial three-dimensional (3D) in vitro tissues, such as functional organs, but also enables the investigation of drug responses in pathological tissue models, that is, in 3D cancer models which are superior to conventional two-dimensional (2D) cell cultures on petri dishes and can overcome the limitations of animal models, thereby reducing the need for preclinical in vivo models. In this thesis, novel 3D CRC models on the basis of a decellularised intestinal matrix were established. In the first part, it could be shown that the cell line SW480 exhibited different characteristics when grown in a 3D environment from those in conventional 2D culture. While the cells showed a mesenchymal phenotype in 2D culture, they displayed a more pronounced epithelial character in the 3D model. By adding stromal cells (fibroblasts), the cancer cells changed their growth pattern and built tumour-like structures together with the fibroblasts, thereby remodelling the natural mucosal structures of the scaffold. Additionally, the established 3D tumour model was used as a test system for treatment with standard chemotherapeutic 5-fluorouracil (5-FU). The second part of the thesis focused on the establishment of a 3D in vitro test system for targeted therapy. The US Food and Drug Administration has already approved of a number of drugs for targeted therapy of specific types of cancer. For instance, the small molecule vemurafenib (PLX4032, Zelboraf™) which demonstrated impressive response rates of 50-80\% in melanoma patients with a mutation of the rapidly accelerated fibrosarcoma oncogene type B (BRAF) kinase which belongs to the mitogen active protein kinase (MAPK) signalling pathway. However, only 5\% of CRC patients harbouring the same BRAF mutation respond to treatment with vemurafenib. An explanation for this unresponsiveness could be a feedback activation of the upstream EGFR, reactivating the MAPK pathway which sustains a proliferative signalling. To test this hypothesis, the two early passage cell lines HROC24 and HROC87, both presenting the mutation BRAF V600E but differing in other mutations, were used and their drug response to vemurafenib and/or gefitinib was assessed in conventional 2D cell culture and compared to the more advanced 3D model. Under 3D culture conditions, both cell lines showed a reduction of the proliferation rate only in the combination therapy approach. Furthermore, no significant differences between the various treatment approaches and the untreated control regarding apoptosis rate and viability for both cell lines could be found in the 3D tumour model which conferred an enhanced chemoresistance to the cancer cells. Because of the observed unresponsiveness to BRAF inhibition by vemurafenib as can be seen in the clinic for patients with BRAF mutations in CRC, the cell line HROC87 was used for further xenografting experiments and analysis of activation changes in the MAPK signalling pathway. It could be shown that the cells presented a reactivation of Akt in the 3D model when treated with both inhibitors, suggesting an escape mechanism for apoptosis which was not present in cells cultured under conventional 2D conditions. Moreover, the cells exhibited an activation of the hepatocyte growth factor receptor (HGFR, c-Met) in 2D and 3D culture, but this was not detectable in the xenograft model. This shows the limitations of in vivo models. The results suggest another feedback activation loop than that to the EGFR which might not primarily be involved in the resistance mechanism. This reflects the before mentioned high attrition rates in the preclinical drug testing.},
  subject      = {Dickdarmtumor},
  language  = {en}
}
@phdthesis{Peindl2024,
  author    = {Peindl, Matthias},
  title     = {Refinement of 3D lung cancer models for automation and patient stratification with mode-of-action studies},
  doi       = {10.25972/OPUS-31069},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-310693},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2024},
  abstract  = {Lung cancer is the main cause of cancer-related deaths worldwide. Despite the availability of several targeted therapies and immunotherapies in the clinics, the prognosis for lung cancer remains poor. A major problem for the low benefit of these therapies is intrinsic and acquired resistance, asking for pre-clinical models for closer investigation of predictive biomarkers for refined personalized medicine and testing of possible combination therapies as well as novel therapeutic approaches to break resistances. One third of all lung adenocarcinoma harbor mutations in the KRAS gene, of which 39 \% are transitions from glycine to cysteine in codon 12 (KRASG12C). Being considered "undruggable" in previous decades, KRASG12C-inhibitors now paved the way into the standard-of-care for lung adenocarcinoma treatment in the clinics. Still, the overall response rates as well as overall survival of patients treated with KRASG12C-inhibitors are sobering. Therefore, 3D KRASG12C-biomarker in vitro models were developed based on a decellularized porcine jejunum (SISmuc) using commercial and PDX-derived cell lines and characterized in regards of epithelial-mesenchymal-transition (EMT), stemness, proliferation, invasion and c-MYC expression as well as the sensitivity towards KRASG12C-inhibiton. The phenotype of lung tumors harboring KRAS mutations together with a c-MYC overexpression described in the literature regarding invasion and proliferation for in vivo models was well represented in the SISmuc models. A higher resistance towards targeted therapies was validated in the 3D models compared to 2D cultures, while reduced viability after treatment with combination therapies were exclusively observed in the 3D models. In the test system neither EMT, stemness nor the c-MYC expression were directly predictive for drug sensitivity. Testing of a panel of combination therapies, a sensitizing effect of the aurora kinase A (AURKA) inhibitor alisertib for the KRASG12C-inhibitor ARS-1620 directly correlating with the level of c-MYC expression in the corresponding 3D models was observed. Thereby, the capability of SISmuc tumor models as an in vitro test system for patient stratification was demonstrated, holding the possibility to reduce animal experiments. Besides targeted therapies the treatment of NSCLC with oncolytic viruses (OVs) is a promising approach. However, a lack of in vitro models to test novel OVs limits the transfer from bench to bedside. In this study, 3D NSCLC models based on the SISmuc were evaluated for their capability to perform efficacy and risk assessment of oncolytic viruses (OVs) in a pre-clinical setting. Hereby, the infection of cocultures of tumor cells and fibroblasts on the SISmuc with provided viruses demonstrated that in contrast to a wildtype herpes simplex virus 1 (HSV-1) based OV, the attenuated version of the OV exhibited specificity for NSCLC cells with a more advanced and highly proliferative phenotype, while fibroblasts were no longer permissive for infection. This approach introduced SISmuc tumor models as novel test system for in vitro validation of OVs. Finally, a workflow for validating the efficacy of anti-cancer therapies in 3D tumor spheroids was established for the transfer to an automated platform based on a two-arm-robot system. In a proof-of-concept process, H358 spheroids were characterized and treated with the KRASG12C-inhibitor ARS-1620. A time- and dose-dependent reduction of the spheroid area after treatment was defined together with a live/dead-staining as easy-to-perform and cost-effective assays for automated drug testing that can be readily performed in situ in an automated system.},
  subject      = {Krebs <Medizin>},
  language  = {en}
}